tiprankstipranks
IOL Chemicals & Pharmaceuticals Ltd. (IN:IOLCP)
:IOLCP
India Market

IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) AI Stock Analysis

2 Followers

Top Page

IN:IOLCP

IOL Chemicals & Pharmaceuticals Ltd.

(IOLCP)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
₹76.00
▼(-9.62% Downside)
Action:ReiteratedDate:11/13/25
The overall stock score of 60 reflects a stable financial position with a strong balance sheet, but challenges in revenue growth and cash flow optimization. Technical indicators suggest a bearish trend, and the valuation indicates moderate pricing with limited dividend income potential. The absence of recent earnings call data or notable corporate events leaves these areas unassessed.
Positive Factors
Strong balance sheet and low leverage
A healthy equity ratio and low leverage give the company lasting financial flexibility to fund capital expenditure, absorb cyclicality in API markets, pursue selective capacity expansions or product investments, and sustain operations without urgent refinancing pressure.
Negative Factors
Declining free cash flow
A decline in free cash flow reduces the firm's ability to self-fund capex, pay dividends, or deleverage. Persistently weak cash conversion can force reliance on external financing or delay strategic investments, constraining long-term growth and financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet and low leverage
A healthy equity ratio and low leverage give the company lasting financial flexibility to fund capital expenditure, absorb cyclicality in API markets, pursue selective capacity expansions or product investments, and sustain operations without urgent refinancing pressure.
Read all positive factors

IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) vs. iShares MSCI India ETF (INDA)

IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company offers active pharmaceutical ingredients (API), such as ibuprofen, ibuprofen lysinate, ibuprofen sodium...
How the Company Makes Money
IOLCP primarily makes money by manufacturing and selling (1) pharmaceutical APIs—most notably ibuprofen—along with other APIs/intermediates, and (2) specialty/industrial chemicals and chemical intermediates. Revenue is generated through business-t...

IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary
IOL Chemicals & Pharmaceuticals Ltd. presents a stable financial position with a robust balance sheet and prudent leverage. However, challenges are evident in maintaining revenue growth and optimizing cash flow. Continued focus on improving profitability and cash management is essential to support long-term growth.
Income Statement
62
Positive
Balance Sheet
75
Positive
Cash Flow
58
Neutral
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue21.70B20.68B21.19B22.02B21.84B19.46B
Gross Profit7.38B6.54B2.70B6.41B5.72B8.22B
EBITDA2.52B2.25B2.61B2.46B2.71B6.11B
Net Income1.16B1.01B1.34B1.39B1.68B4.45B
Balance Sheet
Total Assets24.13B23.82B22.44B20.22B19.62B16.10B
Cash, Cash Equivalents and Short-Term Investments1.79B2.09B1.43B186.40M1.20B3.37B
Total Debt1.59B1.17B327.60M798.10M439.50M27.30M
Total Liabilities6.62B6.94B6.33B5.14B5.70B3.50B
Stockholders Equity17.51B16.88B16.12B15.08B13.92B12.60B
Cash Flow
Free Cash Flow-535.70M-349.30M159.10M-895.50M-602.40M2.72B
Operating Cash Flow110.60M1.79B2.90B1.22B930.50M3.80B
Investing Cash Flow-961.60M-1.54B-1.91B-1.20B-1.21B-3.17B
Financing Cash Flow342.30M460.40M-925.00M-41.10M-16.40M-582.80M

IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price84.09
Price Trends
50DMA
73.07
Positive
100DMA
78.91
Negative
200DMA
87.84
Negative
Market Momentum
MACD
0.77
Negative
RSI
56.35
Neutral
STOCH
64.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Positive. The current price of 84.09 is above the 20-day moving average (MA) of 72.73, above the 50-day MA of 73.07, and below the 200-day MA of 87.84, indicating a neutral trend. The MACD of 0.77 indicates Negative momentum. The RSI at 56.35 is Neutral, neither overbought nor oversold. The STOCH value of 64.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:IOLCP.

IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
₹22.34B24.590.09%15.47%-1.72%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
60
Neutral
₹22.74B29.380.97%5.74%16.06%
53
Neutral
₹25.73B51.390.07%16.88%0.69%
51
Neutral
₹24.58B-310.890.20%-4.37%-82.37%
46
Neutral
₹5.90B-2,425.331.07%-22.10%-85.56%
45
Neutral
₹21.65B-15.050.43%-11.11%-340.74%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
77.47
13.08
20.32%
IN:FAIRCHEMOR
Fairchem Organics Ltd
468.80
-427.63
-47.70%
IN:PRINCEPIPE
Prince Pipes And Fittings Ltd
222.35
-39.00
-14.92%
IN:ROSSARI
Rossari Biotech Ltd
403.40
-223.08
-35.61%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,099.80
389.06
54.74%
IN:TIRUMALCHM
Thirumalai Chemicals Limited
179.55
-89.55
-33.28%

IOL Chemicals & Pharmaceuticals Ltd. Corporate Events

IOL Chemicals & Pharmaceuticals Promoter Group Ups Stake Via Market Purchase
Mar 20, 2026
IOL Chemicals Pharmaceuticals Ltd. disclosed that promoter group entity NCVI Enterprises Ltd. has increased its shareholding in the company through an on-market purchase. NCVI acquired 404,305 equity shares on 19 March 2026, raising its stake fro...
IOL Chemicals & Pharmaceuticals Promoter Group Raises Stake via Market Purchase
Mar 19, 2026
IOL Chemicals and Pharmaceuticals Ltd. has disclosed a change in shareholding by promoter group entity NCVI Enterprises Ltd. under Regulation 7(2) of SEBI’s Prohibition of Insider Trading Regulations, 2015. The filing shows that NCVI Enterpr...
IOL Chemicals & Pharmaceuticals Defends Compliance of Q3 FY2025 Financial Results
Mar 17, 2026
IOL Chemicals Pharmaceuticals has clarified to the National Stock Exchange that its standalone and consolidated financial results for the quarter ended 31 December 2025 were prepared in full compliance with Indian Accounting Standards and the for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 13, 2025